Early academic pursuits 🎓

Jerzy trojan completed his doctorate d’état ès sciences (hdr) at the prestigious sorbonne - p&m curie. during this formative period, he laid the groundwork for his future contributions to biomedical science, specifically in the field of cancerology. his early research endeavors, characterized by a rigorous scientific approach, focused on critical aspects of oncology and laid the foundation for his later groundbreaking work.

Professional endeavors 🏥

Jerzy has held various esteemed positions throughout his career, reflecting his commitment to advancing cancer research. he is currently a visiting professor at the insitm, cancer center, and paris-saclay university in villejuif, france, where he has been since 2019. before this, he served as president and research director at the international cancer gene therapy and oncology diagnostics center (ceadea) in bogota, colombia, and has also held prominent roles in institutions across the usa and europe, including case western reserve university and the sidney kimmel cancer center. these diverse experiences have equipped him with a comprehensive understanding of both the scientific and clinical aspects of cancer treatment.

Contributions and research focus 🔬

Dr. trojan is best known for establishing cancer gene therapy, particularly immuno-gene therapy, as a pivotal domain within oncology. his pioneering research, highlighted in publications from 1993, led to significant advancements in the treatment of glioblastoma, showcasing the therapeutic potential of gene therapy. Immuno - gene therapy additionally, he explored the intersection between neuro-ontogenesis and neuro-oncogenesis, identifying afp and igf-i as novel biomarkers, which have implications for understanding central nervous system differentiation and cancer progression.

Accolades and recognition 🏆

In recognition of his substantial contributions to biomedical science, jerzy was elected as a member of the prestigious french academy of medicine (anm) in paris in 2017. his extensive body of work includes nearly 370 publications, encompassing 140 articles, 102 book chapters, and four books, which have garnered over 3,500 Immuno - gene therapy citations. this impressive scholarly output underscores his impact and influence in the field of cancer research.

Impact and influence 🌍

Dr. trojan's research has significantly shaped the landscape of cancer therapy, particularly in immunotherapy. his establishment of immuno-gene therapy has opened new avenues for treating aggressive cancers, thus influencing both academic research and clinical practices. his work has not only contributed to theoretical Immuno - gene therapy advancements but has also informed practical applications that benefit patients facing challenging diagnoses.

Legacy and future contributions 🔮

With an enduring commitment to advancing cancer research, jerzy trojan continues to influence the field through his current role as a visiting professor and research director. his legacy is evident in the ongoing projects aimed at improving cancer treatment outcomes, particularly through innovative therapeutic strategies. as he continues to publish and mentor the next generation of researchers, his contributions will undoubtedly have a lasting impact on the future of oncology and gene therapy.

Notable Publications

Title: Precancerous Disease Systemic Lupus Erythematosus–The Role of BAFF in Corticosteroids Treatment
Author: J. Trojan et al.
Journal: Medical Research and Its Applications, Vol. 6, Pages 114-127
DOI: 10.9734/bpi/mria/v6/7520C
Publication Date: June 3, 2024

Title: Anti-Gene IGF-I Vaccines in Cancer Gene Therapy: A Review of a Case of Glioblastoma
Author: J. Trojan
Journal: Current Medicinal Chemistry, Vol. 31, Pages 1982-2002
DOI: 10.2174/0109298673231106095141
Publication Date: March 11, 2024

Title: Establishment of Cancer Gene Therapy
Author: J. Trojan
Journal: Cambridge Scholars Publishing
Publication Date: March 2, 2023

Title: Neoplastic brain, glioblastoma and immunotherapy
Author: J. Trojan et al.
Journal: In: Brain and Spinal Tumors - Primary and Secondary, Ed. L.R. Morgan, F.B. Sarica, InTechOpen
Publication Date: 2020

Title: In vitro technical aspects of Anti–Gene IGF-I vaccines against glioma
Author: J. Trojan et al.
Journal: IBR, Vol. 3(1), Pages 43-48
Publication Date: 2019

Prof. Zhiguo Wang - Polypharmacology - Outstanding Scientist Award

Guangdong Provincial Key Laboratory for Mechanistic and Translational Research on Bidirectional Complications among Chronic Conditions, Jinan University, China - China

Author Profile

SCOPUS

ORCID

GOOGLE SCHOLAR

Early academic pursuits 🎓

Zhiguo Wang embarked on his academic journey with a strong foundation in pharmacology, pursuing his studies at Harbin Medical University in Heilongjiang, China. His early work laid the groundwork for a distinguished career focused on understanding chronic diseases and their complex interrelations. His rigorous training and commitment to research established him as a formidable scholar in the field of cardiovascular and chronic disease research.

Professional endeavors 🏢

Throughout his career, Zhiguo has held numerous prestigious positions, demonstrating his leadership in the medical and research communities. He is currently the Director and Professor at the Guangdong Provincial Key Laboratory for Mechanistic and Translational Research on Chronic Disease Complex Complications at Jinan University in Guangzhou, China. His role as a chief scientist and professor across various departments at the First Affiliated Hospital of Jinan University reflects his multifaceted expertise. Additionally, he has contributed significantly as a Distinguished Professor at Harbin Medical University and held a visiting professorship at the Montreal Heart Institute in Canada.

Contributions and research focus 🔬

Zhiguo's research focuses on the mechanistic and translational aspects of chronic diseases, particularly the bidirectional complications arising from these conditions. He has pioneered studies that explore the pathophysiology of cardiovascular diseases and their links to metabolic disorders. His work employs innovative Polypharmacology methodologies to investigate the underlying mechanisms of disease progression and to develop effective therapeutic strategies, aiming to improve patient outcomes in chronic disease management.

Accolades and recognition 🏅

Zhiguo Wang has received numerous accolades for his contributions to medical research, including being a Fellow of the American Heart Association (FAHA) and a Polypharmacology Fellow of the European Society of Cardiology (FESC). His recognition as a Marion L. Munro Research Scholar by the Canadian Diabetes Association further underscores his impactful research in chronic disease mechanisms. His extensive publication record in high-impact journals reflects his influence and standing in the academic community.

Impact and influence 🌍

Zhiguo's research has made a significant impact on the understanding of chronic diseases and their complications, influencing both clinical practice and public health strategies. His work is instrumental in bridging the gap between basic science and clinical applications, ultimately contributing to improved therapeutic approaches Polypharmacology for patients suffering from chronic conditions. He is a sought-after speaker and mentor, inspiring the next generation of researchers in his field.

Legacy and future contributions 🔮

As a leader in chronic disease research, Zhiguo Wang’s legacy is built on his commitment to advancing scientific knowledge and improving patient care. His ongoing research aims to unravel the complexities of chronic disease interactions and to foster innovative therapeutic strategies. With a focus on translational research, Zhiguo's future contributions are poised to drive significant advancements in understanding and treating chronic conditions, leaving a lasting impact on the field and enhancing healthcare outcomes globally.

Notable Publications

Topical GDF11 accelerates skin wound healing in both type 1 and 2 diabetic mouse models 2020(9)

Metformin Shortens Prolonged QT Interval in Diabetic Mice by Inhibiting L-Type Calcium Current 2020(8)

Fibroblast growth factor 21 inhibited ischemic arrhythmias via targeting miR-143/EGR1 axis 2020(38)

Increase of late sodium current contributes to enhanced susceptibility to atrial fibrillation in diabetic mice 2019(22)

Systematic analysis of intestinal microRNAs expression in HCC: Identification of suitable reference genes in fecal samples 2019(4)

Prof. Jerzy trojan – Immuno – gene therapy – Excellence in Innovation

Prof. Jerzy trojan - Immuno - gene therapy - Excellence in Innovation

CEDEA/ICGT and INSERM/Univ. Paris-Saclay - France